We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Immupharma Plc | LSE:IMM | London | Ordinary Share | GB0033711010 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.03 | 1.38% | 2.21 | 2.20 | 2.25 | 2.25 | 2.20 | 2.20 | 1,190,181 | 14:08:31 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Finance Services | 0 | -3.81M | -0.0114 | -1.97 | 7.5M |
TIDMIMM
RNS Number : 1740B
Immupharma PLC
19 September 2018
19 September 2018
ImmuPharma PLC
("ImmuPharma" or the "Company")
Appointment of Joint Brokers
ImmuPharma PLC (AIM: IMM.L), the specialist drug discovery and development company, is pleased to announce that it has, with immediate effect, appointed Stanford Capital Partners and SI Capital as joint brokers. They will work in conjunction with Northland Capital Partners who are the Company's NOMAD and broker.
Commenting on the announcement, Tim McCarthy, Chairman of ImmuPharma said:
"As per our recently announced corporate update, we are looking forward with confidence to the future progress of ImmuPharma. As part of our continued proactive investor relations strategy, we also look forward to working with Stanford Capital and SI Capital as part of our corporate advisory team."
For further information please contact: + 44 (0) 20 ImmuPharma plc (www.immupharma.co.uk) 7152 4080 Tim McCarthy, Chairman + 44 (0) 7721 Lisa Baderoon, Head of Investor Relations 413496 Northland Capital Partners Limited (NOMAD & Joint +44 (0)20 3861 Broker) 6625 David Hignell, Dugald Carlean, Jamie Spotswood, Corporate Finance Rob Rees, Corporate Broking Stanford Capital Partners (Joint Broker) +44 (0) 20 Patrick Claridge 3815 8880 Chris Coleman SI Capital (Joint Broker) +44 (0) 1483 Nick Emerson 413500
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
APPFKFDDABKDQCD
(END) Dow Jones Newswires
September 19, 2018 02:01 ET (06:01 GMT)
1 Year Immupharma Chart |
1 Month Immupharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions